Imfinzi

News

AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.

News

AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage gastric cancer.

News

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.

News

AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug.

News

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in early bladder cancer.

News

AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to its top-seller Tagrisso.